Takeda, Drug Prices & Medicare Spending

Takeda manufactures 18 drugs tracked by Medicare Part D with total spending of $8.1B.

Drugs Tracked

$8.1B

Medicare Spending

$249.24

Avg Cost/Claim

94%

Have Generics

Takeda Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Entyvio	Vedolizumab	$6,319.00	$1.6B	+14.6%	Yes
2	Vyvanse	Lisdexamfetamine	$238.00	$1.3B	-18.4%	Yes
3	Trintellix	Vortioxetine	$278.00	$1.1B	+7.8%	No
4	Ninlaro	Ixazomib	$7,884.00	$678.0M	-4.5%	Yes
5	Advate	Antihemophilic Factor (rDNA)	$25,333.00	$456.0M	-14.6%	Yes
6	Mydayis	Mixed Amphetamine Salts ER	$205.00	$345.0M	+12.4%	Yes
7	Dexilant	Dexlansoprazole	$139.00	$345.0M	-14.2%	Yes
8	Colcrys	Colchicine	$139.00	$345.0M	-14.6%	Yes
9	Velcade	Bortezomib	$5,074.00	$345.0M	-22.4%	Yes
10	Adynovate	Antihemophilic Factor (PEG)	$24,643.00	$345.0M	-6.2%	Yes
11	Uloric	Febuxostat	$126.00	$234.0M	-28.4%	Yes
12	Intuniv	Guanfacine ER	$144.00	$178.0M	-22.4%	Yes
13	Motegrity	Prucalopride	$206.00	$178.0M	+22.4%	Yes
14	Edarbi	Azilsartan	$144.00	$178.0M	-8.4%	Yes
15	Actos	Pioglitazone	$30.00	$145.0M	-28.4%	Yes
16	Prevacid	Lansoprazole	$50.00	$123.0M	-34.2%	Yes
17	Nesina	Alogliptin	$142.00	$123.0M	-14.6%	Yes
18	Pioglitazone	Pioglitazone	$36.00	$89.0M	-28.4%	Yes

Frequently Asked Questions

Takeda manufactures 18 drugs tracked by Medicare Part D, with total annual spending of $8.1B.

Advate (Antihemophilic Factor (rDNA)) is the most expensive at $25,333.00 per claim.

17 of 18 Takeda drugs (94%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.